ArticlePharmacology research & perspectives2026
Paeonol Inhibits Cell Growth by Inducing Ferroptosis in Human Glioma Cells.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of machine learning approaches for predicting sickle cell crisis and mortality risk at the climate-health nexus.BMC medical informatics and decision making · 2026Pooled it
- Metabolic Reprogramming and Neurotransmitter Signaling Co-Option in the Glioma Immune Microenvironment: Dual-Axis Regulation of Immunosuppression.Biomolecules · 2026Review
- Paeonol Inhibits Cell Growth by Inducing Ferroptosis in Human Glioma Cells.Pharmacology research & perspectives · 2026Article
- Valproic acid sensitizes resveratrol to induce glioma cell apoptosis via the ROS-PDCD4-Bax signaling axis.Frontiers in cell and developmental biology · 2026Article
- Bioengineering Strategies to Address Key Bottlenecks in Ferroptosis-Based Cancer Therapy: A Critical Review.International journal of nanomedicine · 2026Review
- Targeting glutathione peroxidase 4 in ferroptosis: from immune regulation to pharmacological development and translational applications.Frontiers in pharmacology · 2026Review
- Ferroptosis-neuroinflammation interplay: mechanistic pathways and therapeutic opportunities in central nervous system disorders.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Paeonol (PAE), a phenolic phytochemical derived from traditional Chinese medicinal plants, exhibits multifaceted pharmacological properties including demonstrated antitumor efficacy against hepatic, gastric, and breast carcinomas. However, its therapeutic potential in glioma remains unexplored. Ferroptosis, a regulatory cell death pathway dependent on iron content mediated through lethal lipid peroxidation, has become a prospective method for targeted treatment of drug-resistant malignant tumors. This study confirmed that PAE is a new inducer of ferroptosis in human glioma cells. Inhibition of glioma proliferation, migration, and invasion was observed. Mechanistically, PAE depletes lipid droplets (LDs) and amplifies cytotoxic lipid peroxides (LPO) and reactive oxygen species (ROS); caspase-independent cell death was achieved. Crucially, ferroptosis inhibitors (ferrostatin-1, α-tocopherol) reversed PAE's antineoplastic roles, confirming pathway specificity. These findings position PAE as a dual-action agent capable of simultaneously inducing ferroptosis and impeding metastatic spread, offering a mechanistically distinct approach to overcome temozolomide resistance in glioma therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.